Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHM. Vermeulen MA, et al. Among authors: slaets l. Eur J Cancer. 2017 Sep;82:219-227. doi: 10.1016/j.ejca.2017.01.034. Epub 2017 Mar 11. Eur J Cancer. 2017. PMID: 28292559
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Dinjens WN, van Marion R, van Diest PJ, Martens JW, van Deurzen CH. Doebar SC, et al. Among authors: slaets l. Mod Pathol. 2017 Apr;30(4):509-518. doi: 10.1038/modpathol.2016.229. Epub 2017 Jan 13. Mod Pathol. 2017. PMID: 28084333 Free article.
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC, Kuijer A, Straver ME, Slaets L, Litiere S, Viale G, Van't Veer LJ, Glas AM, Delorenzi M, van Dalen T, Tryfonidis K, Piccart MJ, Cardoso F, Rutgers EJ; TRANSBIG Consortium and the MINDACT Investigators. Aalders KC, et al. Among authors: slaets l. Eur J Cancer. 2017 Jul;79:98-105. doi: 10.1016/j.ejca.2017.03.034. Epub 2017 May 3. Eur J Cancer. 2017. PMID: 28477490 Clinical Trial.
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Lago LD, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH. Cardoso F, et al. Among authors: slaets l. Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651. Ann Oncol. 2018. PMID: 29092024 Free PMC article.
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, Pijnappel RM, Bijker N, Rutgers EJ, Wesseling J. Elshof LE, et al. Among authors: slaets l. Eur J Cancer. 2015 Aug;51(12):1497-510. doi: 10.1016/j.ejca.2015.05.008. Epub 2015 May 26. Eur J Cancer. 2015. PMID: 26025767 Free article. Clinical Trial.
An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®).
Makama M, Drukker CA, Rutgers EJT, Slaets L, Cardoso F, Rookus MA, Tryfonidis K, Van't Veer LJ, Schmidt MK. Makama M, et al. Among authors: slaets l. Eur J Cancer. 2017 Apr;75:5-13. doi: 10.1016/j.ejca.2016.12.024. Epub 2017 Feb 16. Eur J Cancer. 2017. PMID: 28214658 Clinical Trial.
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F; MINDACT investigators. Viale G, et al. Among authors: slaets l. Breast Cancer Res Treat. 2018 Jan;167(1):123-131. doi: 10.1007/s10549-017-4509-9. Epub 2017 Sep 19. Breast Cancer Res Treat. 2018. PMID: 28929359 Clinical Trial.
Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®)" [Eur J Cancer 75 (April 2017) 5-13].
Makama M, Drukker CA, Rutgers EJT, Slaets L, Cardoso F, Rookus MA, Tryfonidis K, Van't Veer LJ, Schmidt MK. Makama M, et al. Among authors: slaets l. Eur J Cancer. 2018 Jun;96:131-132. doi: 10.1016/j.ejca.2018.03.017. Epub 2018 Apr 12. Eur J Cancer. 2018. PMID: 29656866 No abstract available.
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.
Viale G, Slaets L, de Snoo FA, Bogaerts J, Russo L, van't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Dell'Orto P, Glas AM, Cardoso F. Viale G, et al. Among authors: slaets l. Breast Cancer Res Treat. 2016 Feb;155(3):463-9. doi: 10.1007/s10549-016-3690-6. Epub 2016 Jan 28. Breast Cancer Res Treat. 2016. PMID: 26820652 Free PMC article. Clinical Trial.
26 results